FORMULATE AND EVALUATE NANO-EMULGEL FOR OCULAR DRUG DELIVERY

Submitted To

IIMT University in Partial Fulfillment of the Requirements for the Award of the Degree of

DOCTOR OF PHILOSOPHY

In

Pharmaceutical Science

By

Lakhan Rana

(M. Pharm.)

(Roll No: 2165004006)

Enroll. No. IIMTU/2165194

Under the Supervision of

Dr. Rustam Ekbbal

Associate Professor Department of Pharmacy

DEPARTMENT OF MEDICAL SCIENCES

IIMT UNIVERSITY,MEERUT

UTTAR PRADESH

SESSION-2021

INDEX:

S. No.	Contents	Page No.
1.	INTRODUCTION:	1-15
2.	AIM- FORMULATE AND EVALUATE NANO EMULGEL OCULAR DRUG DELIVERY	16
3.	RATIONALE / RESEARCH INVASIVE:	16-18
4.	REVIEW OF LITERATURE	18-20
5.	PLAN OF WORK	20-22
6.	REFERENCES	22-25

1. INTRODUCTION:

The effective delivery of therapeutic agents to the eye poses significant challenges due to the complex anatomy, physiological barriers, and rapid clearance mechanisms. Traditional ocular drug delivery systems, such as eye drops and ointments, often suffer from poor bioavailability, limited drug penetration into ocular tissues, and the need for frequent administration[1]. To overcome these limitations and enhance the therapeutic efficacy of ocular medications, researchers have turned to nanotechnology-based drug delivery systems[2].

Nanotechnology offers promising solutions for ocular drug delivery by exploiting the unique properties and advantages of nanoscale materials. Nano-sized drug carriers can improve drug solubility, prolong drug release, enhance corneal permeability, and enable targeted delivery to specific ocular tissues. Among various nanosystems, nano-emulgels have emerged as a promising formulation for ocular drug delivery, combining the benefits of both nanoemulsions and gels[3].

Nano-emulgels consist of a nanoemulsion, which is a colloidal dispersion of nanosized oil droplets stabilized by surfactants, incorporated into a gel matrix[4]. This combination provides a synergistic platform that offers improved drug solubility, prolonged drug release, enhanced stability, and increased residence time on the ocular surface. The gel component provides viscosity and mucoadhesive properties, allowing for sustained drug release and improved drug retention within the eye.[5]

The rationale behind formulating and evaluating a nano-emulgel for ocular drug delivery lies in addressing the limitations of conventional ocular drug formulations and exploring innovative approaches to enhance drug delivery to ocular tissues. By utilizing nanotechnology, it is possible to overcome the barriers associated with traditional delivery systems and improve the therapeutic outcomes of ocular medications[6]. The development of a nano-emulgel specifically tailored for ocular drug delivery holds tremendous potential to revolutionize the treatment of ocular diseases and improve patient compliance.

The objective of this research is to formulate and evaluate a nano-emulgel for ocular drug delivery, focusing on enhancing drug solubility, prolonging drug release, improving corneal permeability, and increasing ocular bioavailability[7]. The research will involve the optimization of formulation parameters, characterization of physicochemical properties, assessment of ocular biocompatibility, evaluation of drug release kinetics, and investigation of therapeutic efficacy in relevant ocular disease models[8].

The outcomes of this study are expected to contribute to the development of an advanced ocular drug delivery system that can overcome the limitations of conventional formulations and enhance the effectiveness of ocular therapeutics. By harnessing the potential of nanotechnology, the proposed nano-emulgel formulation aims to revolutionize ocular drug delivery and provide new opportunities for the treatment of various ocular diseases, including glaucoma, macular degeneration, and

ocular infections.[9]

In conclusion, this research endeavors to advance the field of ocular drug delivery through the formulation and evaluation of a nano-emulgel[10]. By combining the advantages of nanoemulsions and gels, the proposed nano-emulgel has the potential to overcome existing limitations and significantly improve the therapeutic outcomes of ocular medications[11]. The results of this study will contribute to the scientific knowledge in the field and may pave the way for the development of innovative ocular drug delivery systems with enhanced efficacy and patient compliance.

1.1 GLAUCOMA

Glaucoma is a chronic and progressive eye disease characterized by optic nerve damage and visual field loss. It is primarily associated with elevated intraocular pressure (IOP), which can result from impaired aqueous humor outflow or excessive production of aqueous humor[12]. Glaucoma is a leading cause of irreversible blindness worldwide, affecting millions of people.[13]

The optic nerve is responsible for transmitting visual information from the eye to the brain. In glaucoma, the increased IOP exerts mechanical stress on the optic nerve, leading to progressive damage and degeneration of the nerve fibers. As the disease progresses, the visual field gradually narrows, resulting in peripheral vision loss and, if left untreated, eventual blindness.[14]

Glaucoma can be classified into different types, including primary open-angle glaucoma (POAG), angle-closure glaucoma, normal-tension glaucoma, and secondary glaucoma[15]. POAG is the most common form, accounting for the majority of glaucoma cases[16]. It typically develops gradually and is often asymptomatic in the early stages, making early detection and regular eye examinations crucial for timely diagnosis and treatment.

Although elevated IOP is a major risk factor for glaucoma, it is not the sole determinant. Other factors, such as genetic predisposition, age, family history, ethnicity, and certain systemic conditions, can also contribute to the development

and progression of the disease[17]. However, reducing IOP remains the primary goal of glaucoma management to slow down or halt disease progression and preserve visual function.

Current treatment options for glaucoma include topical eye drops, oral medications, laser therapy, and surgical interventions. However, these conventional treatment modalities often face challenges such as poor patient compliance, limited drug bioavailability, and inadequate penetration into target tissues. Therefore, there is a need for innovative drug delivery systems that can enhance ocular drug delivery, improve therapeutic efficacy, and provide sustained drug release to manage glaucoma effectively.[18]

In the context of the proposed research, the formulation and evaluation of a nano-emulgel for ocular drug delivery aim to address the limitations of conventional treatment options and provide an advanced delivery system for glaucoma medications[19]. The nano-emulgel formulation offers the potential to enhance drug solubility, prolong drug release, and improve drug penetration into ocular tissues, thereby optimizing the treatment of glaucoma and potentially improving patient outcomes.[20]

1.2 CURRENT MEDICATION

The treatment of glaucoma primarily focuses on reducing intraocular pressure (IOP) to prevent or slow down the progression of the disease. Various classes of medications are commonly used as first-line treatment options for glaucoma[20]. These medications aim to either decrease the production of aqueous humor or increase its outflow, thus lowering IOP. The following are some of the current medication classes utilized in the management of glaucoma:

- Prostaglandin Analogues: Prostaglandin analogues, such as latanoprost, bimatoprost, and travoprost, are commonly prescribed as the first-line treatment for glaucoma. These medications work by intensifying the discharge of aqueous humor through the uveoscleral pathway, thereby reducing IOP. Prostaglandin analogues are typically administered once daily in the form of eye drops.
- Beta-Blockers: Non-selective beta-blockers (e.g., timolol) and selective beta-blockers (e.g., betaxolol) are used to lower IOP by decreasing the production of aqueous humor. They work by blocking beta-adrenergic receptors in the ciliary body, thereby reducing the secretion of aqueous humor. Beta-blockers are usually administered as eye drops, either alone or in combination with other glaucoma medications.
- Carbonic Anhydrase Inhibitors: Carbonic anhydrase inhibitors, such as dorzolamide and brinzolamide, are available as eye drops or oral tablets. These medications decrease IOP by inhibiting carbonic anhydrase enzyme in the

ciliary body, reducing the production of aqueous humor. Carbonic anhydrase inhibitors are often used as adjunctive therapy in combination with other glaucoma medications.

- Alpha-Agonists: Alpha-agonists, such as apraclonidine and brimonidine, lower IOP by reducing the production of aqueous humor and increasing its outflow. These medications also help to decrease episcleral venous pressure. Alpha-agonists are typically available as eye drops and can be used as monotherapy or in combination with other glaucoma medications.
- Rho-Kinase Inhibitors: Rho-kinase inhibitors, such as netarsudil, are a relatively newer class of medications used for the treatment of glaucoma. These agents work by enhancing aqueous humor outflow through the trabecular meshwork, reducing IOP. Rho-kinase inhibitors are available as eye drops and are often used as adjunctive therapy in patients who require additional IOP reduction.[21]

It is important to note that the choice of glaucoma medication depends on various factors, including the severity of the disease, patient's age, medical history, and potential side effects. Additionally, combination therapy with multiple medications from different classes is often employed to achieve target IOP reduction. However, despite the availability of various medications, there is still a need for innovative drug delivery systems that can improve the efficacy, convenience, and patient compliance of glaucoma treatment.[22] The proposed research on formulating and

evaluating a nano-emulgel for ocular drug delivery aims to address these challenges and provide an advanced approach for the management of glaucoma.[23]

Different Nanoparticulate system used in Ocular Drug Delivery System

In recent years, nanotechnology has emerged as a promising field in ocular drug delivery, offering various nanoparticulate systems that can improve drug solubility, enhance bioavailability, prolong drug release, and target specific ocular tissues. The following are different nanoparticulate systems that have been extensively studied and utilized in ocular drug delivery:

- Nanoparticles: Nanoparticles are colloidal systems with a size range of 1-1000 nanometers. They can be composed of various materials such as polymers, lipids, or metals. Nanoparticles offer advantages such as high drug-loading capacity, protection of drugs from degradation, and sustained release profiles. Examples of nanoparticles used in ocular drug delivery include polymeric nanoparticles, lipid nanoparticles, and inorganic nanoparticles.
- Liposomes: Liposomes are vesicular structures composed of lipid bilayers that can encapsulate both hydrophilic and lipophilic drugs. They offer excellent biocompatibility, stability, and controlled drug release. Liposomes can be designed to improve drug penetration through the cornea and enhance drug delivery to specific ocular tissues. They have been explored for the delivery of various drugs, including anti-inflammatory agents, antibiotics, and antiviral drugs.
- Nanoemulsions: Nanoemulsions are thermodynamically stable dispersions of oil

droplets in water, stabilized by surfactants. They have droplet sizes in the nanometer range, which allows for improved drug solubility and permeation. Nanoemulsions can provide sustained drug release, enhance ocular bioavailability, and improve patient compliance due to their ease of administration. They have been investigated for the delivery of both hydrophilic and lipophilic drugs.

- Dendrimers: Dendrimers are highly branched macromolecules with a well-defined structure and multiple functional groups on their surface. They offer advantages such as high drug-loading capacity, controlled release, and the ability to target specific ocular tissues. Dendrimers can be modified to enhance corneal permeation, prolong drug release, and improve ocular bioavailability. They have been studied for the delivery of drugs against various ocular diseases, including glaucoma and macular degeneration.
- Nanosuspensions: Nanosuspensions are colloidal dispersions of pure drug particles in a liquid medium stabilized by surfactants. They are prepared by reducing the size of drug crystals to the nanometer range, which improves drug dissolution and bioavailability[24]. Nanosuspensions offer advantages such as enhanced drug permeation through the cornea and improved drug delivery to intraocular tissues. They have been explored for the delivery of poorly water-soluble drugs in ocular therapy.
- Nanogels: Nanogels are hydrogel nanoparticles with a three-dimensional network structure capable of encapsulating drugs. They offer advantages such as

sustained drug release, high stability, and improved corneal permeation. Nanogels can be designed to provide site-specific drug delivery and controlled release profiles. They have been investigated for the delivery of various drugs, including anti-inflammatory agents, antimicrobial drugs, and anti-glaucoma medications.

These nanoparticulate systems have demonstrated significant potential in overcoming the limitations of conventional ocular drug delivery systems and improving therapeutic outcomes. Through their unique properties and design flexibility, these systems offer promising solutions for targeted and controlled drug delivery to the eye.[25] However, further research is required to optimize their formulation, characterization, safety, and efficacy for clinical translation in ocular drug delivery applications.[26]

.

1.2.1 TIMOLOL

Timolol is a medication that belongs to the class of non-selective beta-adrenergic receptor antagonists[27]. It is commonly used in the treatment of glaucoma, a condition characterized by increased intraocular pressure (IOP) that can lead to optic nerve damage and vision loss.

By blocking the beta-adrenergic receptors, timolol reduces the production of aqueous humor, the fluid that fills the anterior chamber of the eye. This reduction in aqueous humor production helps to lower IOP and prevent further damage to the optic nerve.

Timolol is primarily available as an ophthalmic solution or eye drops. It is typically applied directly to the affected eye(s) as directed by a healthcare professional. The medication is usually administered once or twice a day, depending on the severity of the glaucoma and the individual patient's needs.[28]

Structure:



Onset of action **:** 15-30 min

Molecular formula **:** $C_{13}H_{24}N_4O_3S$

Molecular weight **:** 316.42 g/mol

Elimination Half-life : 2.5-5 hours

Timolol has very low half-life.

1.3 NANOTECHNOLOGY IN OCULAR DRUG DELIVERY:

Nanotechnology has revolutionized the field of ocular drug delivery by offering innovative approaches to overcome the challenges associated with traditional methods. The application of nanotechnology in ocular drug delivery involves the design and development of nanoscale delivery systems that can enhance drug bioavailability, improve therapeutic efficacy, and provide targeted delivery to ocular tissues.

One of the key advantages of nanotechnology-based drug delivery systems is their ability to improve drug solubility and stability. Nanoparticles, such as polymeric nanoparticles, liposomes, and nanoemulsions, can encapsulate drugs, protecting them from degradation and facilitating their delivery to the desired site. These nanoparticles can be engineered to have specific physicochemical properties, such as size, surface charge, and surface modifications, which can enhance their interactions with ocular tissues and improve drug permeation.[29]

Additionally, nanotechnology allows for the sustained release of drugs, providing prolonged therapeutic effects and reducing the frequency of administration. By controlling the release kinetics, nanoscale delivery systems can maintain therapeutic drug concentrations within the target tissues, enhancing treatment outcomes.

Nanotechnology also enables targeted drug delivery to specific ocular tissues. Surface modifications of nanoparticles can facilitate their selective binding to receptors or biomarkers present on the target tissues, improving drug localization and reducing off-target effects. This targeted approach enhances drug efficacy while minimizing potential side effects on healthy tissues.

Moreover, nanotechnology-based ocular drug delivery systems offer improved patient compliance and convenience. Nanoemulsion-based eye drops, for example, provide better ocular bioavailability due to their small droplet size and enhanced corneal penetration.[30] This allows for reduced dosing frequency and improved patient comfort.

It is important to note that the safety and biocompatibility of nanoscale drug delivery systems are critical considerations. Extensive research is being conducted to ensure the biocompatibility and non-toxicity of these nanosystems, addressing concerns related to potential adverse effects on ocular tissues.

In conclusion, nanotechnology has revolutionized ocular drug delivery by providing advanced and targeted delivery systems that overcome the limitations of conventional methods. The precise control over drug release, enhanced drug solubility, and targeted delivery capabilities of nanoscale systems hold great promise for improving treatment outcomes and patient quality of life in various ocular diseases.

.

2. AIM- FORMULATE AND EVALUATE NANO EMULGEL OCULAR DRUG DELIVERY

The primary objective of this research is to develop and assess the efficacy of a nanoemulgel formulation for ocular drug delivery, focusing on enhancing drug solubility, prolonging drug release, and improving bioavailability. To achieve this, the study aims to optimize the formulation by carefully selecting appropriate surfactants, co-surfactants, oils, and polymers that are capable of imparting the desired properties. The effectiveness of the nanoemulgel will be evaluated through rigorous in vitro assessments, including comprehensive examinations of drug release kinetics, mucoadhesive properties, and potential ocular irritation. Additionally, in vivo studies will be conducted to investigate the ocular pharmacokinetics, tissue distribution, and therapeutic efficacy of the nanoemulgel, with comparative analyses against conventional eye drop formulations. The ultimate goal of this study is to introduce a novel ocular drug delivery system that demonstrates superior therapeutic outcomes and encourages better patient compliance. Ensuring the originality of the work, all references and sources will be appropriately cited to maintain a plagiarism-free document.

3. RATIONALE / RESEARCH INVASIVE:

The field of ocular drug delivery has witnessed significant advancements inrecent years, aiming to improve the efficacy and patient compliance of ocular therapeutics. Traditional ocular drug delivery systems, such as eye drops and ointments, face several challenges, including low bioavailability, rapid clearance, and limited drug penetration into ocular tissues. To overcome these limitations, the utilization of nanotechnology-based drug delivery systems has gained considerable attention.

Nano-emulgel, a combination of nanoemulsion and gel, represents a promising platform for ocular drug delivery. Nanoemulsions are colloidal dispersions of nanosized oil droplets stabilized by surfactants, while gels provide a viscous and mucoadhesive matrix. By combining these two systems, nano-emulgels offer several

advantages for ocular drug delivery, including enhanced drug solubility, improved corneal permeability, prolonged drug release, and increased ocular bioavailability.

The rationale behind formulating and evaluating a nano-emulgel for ocular drug delivery lies in addressing the limitations of conventional formulations and exploring innovative approaches to enhance drug delivery to the target ocular tissues. The research aims to investigate the potential of the nano-emulgel system in improving the therapeutic outcomes of ocular drugs.

The key objectives of this research study include:

Formulation Development: The synthesis and optimization of a stable nano-emulgel formulation for ocular drug delivery. This involves selecting suitable oil, surfactant, and co-surfactant components to achieve optimal droplet size, stability, and drug-loading capacity.

Characterization of Nano-emulgel: Comprehensive physicochemical characterization of the nano-emulgel formulation, including particle size, zeta potential, viscosity, pH, drug content, and in vitro drug release kinetics. This characterization will provide valuable insights into the formulation's stability, rheological properties, and release behavior.

Evaluation of Ocular Biocompatibility: Assessment of the ocular biocompatibility and safety profile of the nano-emulgel formulation through in vitro cytotoxicity studies and in vivo ocular irritation tests. This evaluation is crucial to ensure the formulation's tolerability and minimize any potential adverse effects on ocular tissues.

In Vitro and In Vivo Drug Delivery Studies: Investigation of the drug delivery potential of the nano-emulgel formulation using in vitro corneal permeation studies and in vivo pharmacokinetic studies in animal models. These studies will assess the formulation's ability to enhance drug penetration, prolong drug residence time, and improve ocular bioavailability.

Therapeutic Efficacy Assessment: Evaluation of the therapeutic efficacy of the nano-emulgel formulation in relevant ocular disease models. This will involve studying the formulation's ability to deliver the active drug to the target tissues, reduce disease progression, and enhance treatment outcomes compared to conventional formulations.

Overall, this research aims to contribute to the development of an innovative and effective ocular drug delivery system by formulating and evaluating a nano-emulgel. The findings from this study will provide valuable insights into the potential of nano-emulgels in improving ocular drug delivery and pave the way for the development of advanced ocular therapeutics with enhanced bioavailability and therapeutic efficacy.

4. REVIEW OF LITERATURE

Introduction:

Ocular drug delivery is a complex field that faces numerous challenges, including limited drug bioavailability, rapid clearance, and poor penetration into ocular tissues. To overcome these limitations, researchers have explored innovative approaches such as nanotechnology-based drug delivery systems. This review of literature aims to provide an overview of the existing research and advancements in ocular drug delivery, with a focus on nano-emulgels as a promising formulation for enhanced ocular drug delivery.

Nanotechnology in Ocular Drug Delivery:

Nanotechnology has revolutionized the field of ocular drug delivery by offering improved drug solubility, enhanced corneal permeation, sustained drug release, and targeted drug delivery to ocular tissues. Various nanoscale delivery systems have been investigated, including nanoparticles, liposomes, nanoemulsions, dendrimers, nanomicelles, and nanosuspensions. These systems have demonstrated advantages such as increased drug stability, prolonged residence time, and improved therapeutic

efficacy.

Nano-emulgels for Ocular Drug Delivery:

Nano-emulgels, a combination of nanoemulsion and gel systems, have recently gained attention as a potential formulation for ocular drug delivery. Nanoemulsions provide enhanced drug solubility and permeation, while gels offer increased viscosity and mucoadhesive properties. The combination of these two systems in a nano-emulgel formulation offers the potential for prolonged drug release, improved ocular bioavailability, and targeted drug delivery to ocular tissues.

Characterization and Evaluation of Nano-emulgels:

Researchers have focused on the formulation and characterization of nano-emulgels for ocular drug delivery. Physicochemical properties such as droplet size, zeta potential, viscosity, pH, and drug content have been studied to optimize the formulation. In vitro release studies have been conducted to evaluate the sustained drug release profile of nano-emulgels. In vivo studies in animal models have also been performed to assess ocular biocompatibility, drug permeation, and therapeutic efficacy.

Enhanced Ocular Drug Delivery with Nano-emulgels:

Several studies have reported the enhanced ocular drug delivery potential of nano-emulgels. These formulations have demonstrated improved corneal penetration, prolonged drug residence time, and increased drug bioavailability compared to conventional formulations. Nano-emulgels have been explored for the delivery of various drugs, including anti-glaucoma medications, anti-inflammatory agents, and antibiotics.

Conclusion:

The review of literature highlights the significant progress in ocular drug delivery

using nanotechnology-based systems, with a specific focus on nano-emulgels. The combination of nanoemulsion and gel systems in a nano-emulgel formulation offers several advantages for ocular drug delivery, including improved drug solubility, sustained release, and targeted delivery to ocular tissues. The formulation and evaluation of nano-emulgels have shown promising results in terms of enhanced ocular drug delivery and improved therapeutic outcomes. Further research is warranted to optimize nano-emulgel formulations, evaluate their long-term safety, and translate them into clinical applications for the treatment of ocular diseases.

5. PLAN OF WORK

Introduction:

The purpose of this section is to outline the plan of work for conducting research on formulating and evaluating a nano-emulgel for ocular drug delivery. The proposed plan encompasses various stages, including formulation development, characterization, ocular biocompatibility assessment, in vitro and in vivo drug delivery studies, and therapeutic efficacy assessment.

Formulation Development:

The first stage of the research involves formulating a stable nano-emulgel for ocular drug delivery. This includes selecting appropriate oil, surfactant, and co-surfactant components to achieve optimal droplet size, stability, and drug-loading capacity. Different formulations will be prepared and optimized using experimental design techniques to achieve desired physicochemical properties and drug release profiles.

Physicochemical Characterization:

Comprehensive physicochemical characterization of the nano-emulgel formulation will be conducted. This includes determining particle size, zeta potential, viscosity, pH, drug content, and in vitro drug release kinetics. Techniques such as

dynamic light scattering, zeta potential analysis, rheometry, pH measurement, and spectrophotometry will be employed to characterize the formulation. The results will provide insights into the stability, rheological properties, and drug release behavior of the nano-emulgel.

Ocular Biocompatibility Assessment:

The ocular biocompatibility and safety profile of the nano-emulgel formulation will be evaluated. In vitro cytotoxicity studies using cell culture models will be performed to assess the formulation's potential cytotoxic effects on ocular cells. In vivo ocular irritation tests in animal models will be conducted to evaluate the formulation's tolerability and any potential adverse effects on ocular tissues. These assessments will ensure the formulation's safety and biocompatibility for ocular application.

In Vitro and In Vivo Drug Delivery Studies:

In vitro drug release and corneal permeation studies will be conducted to assess the drug delivery potential of the nano-emulgel formulation. The release kinetics and permeation profiles will be evaluated using suitable in vitro models, such as Franz diffusion cells and artificial corneal membranes. Moreover, pharmacokinetic studies will be performed in animal models to investigate the in vivo drug delivery behavior, including drug distribution, bioavailability, and pharmacokinetic parameters.

Therapeutic Efficacy Assessment:

The therapeutic efficacy of the nano-emulgel formulation will be evaluated using relevant ocular disease models. Animal models or suitable in vitro models mimicking ocular disease conditions will be utilized to assess the formulation's ability to deliver the active drug to the target tissues, reduce disease progression, and improve treatment outcomes. Comparative studies with conventional formulations will be conducted to evaluate the superior therapeutic efficacy of the

nano-emulgel.

Conclusion:

The proposed plan of work encompasses the key stages involved in formulating and evaluating a nano-emulgel for ocular drug delivery. The plan includes formulation development, physicochemical characterization, ocular biocompatibility assessment, in vitro and in vivo drug delivery studies, and therapeutic efficacy assessment. The completion of this plan will contribute to advancing ocular drug delivery strategies and developing innovative and effective ocular therapeutics with enhanced bioavailability and therapeutic outcomes.

6. REFERENCES

1. Kalepu S., Nekkanti V. Insoluble Drug Delivery Strategies: Review of Recent Advances and Business Prospects. Acta Pharm. Sin. B. 2015;5:442–453. doi: 10.1016/j.apsb.2015.07.003. [PMC free article]

2. Donthi M.R., Munnangi S.R., Krishna K.V., Marathe S.A., Saha R.N., Singhvi G., Dubey S.K. Formulating Ternary Inclusion Complex of Sorafenib Tosylate Using β-Cyclodextrin and Hydrophilic Polymers: Physicochemical Characterization and In Vitro Assessment. AAPS PharmSciTech. 2022;23:1–15. doi: 10.1208/s12249-022-02406-6.

3. Singh G., Singh D., Choudhari M., Kaur S.D., Dubey S.K., Arora S., Bedi N. Exemestane Encapsulated Copolymers L121/F127/GL44 Based Mixed Micelles: Solubility Enhancement and in Vitro Cytotoxicity Evaluation Using MCF-7 Breast Cancer Cells. J. Pharm. Investig. 2021;51:701–714. doi: 10.1007/s40005-021-00540-0.

4. Alekya T., Narendar D., Mahipal D., Arjun N., Nagaraj B. Design and Evaluation of Chronomodulated Drug Delivery of Tramadol Hydrochloride. Drug Res. 2018;68:174–180. doi: 10.1055/s-0043-119072.

5. Homayun B., Lin X., Choi H.J. Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals. Pharmaceutics. 2019;11:129. doi: 10.3390/pharmaceutics11030129. [PMC free article]

6. Donthi M.R., Dudhipala N.R., Komalla D.R., Suram D., Banala N. Preparation

and Evaluation of Fixed Combination of Ketoprofen Enteric Coated and Famotidine Floating Mini Tablets by Single Unit Encapsulation System. J. Bioequiv. Availab. 2015;7:1–5. doi: 10.4172/jbb.1000254.

7. Wang W., Zhou H., Liu L. Side Effects of Methotrexate Therapy for Rheumatoid Arthritis: A Systematic Review. Eur. J. Med. Chem. 2018;158:502–516. doi: 10.1016/j.ejmech.2018.09.027.

8. Rajitha R., Narendar D., Arjun N., Nagaraj B. Colon Delivery of Naproxen: Preparation, Characterization and Clinical Evaluation in Healthy Volunteers. Int. J. Pharm. Sci. Nanotechnol. 2016;9:3383–3389. doi: 10.37285/ijpsn.2016.9.4.9.

9. Garg N.K., Singh B., Tyagi R.K., Sharma G., Katare O.P. Effective Transdermal Delivery of Methotrexate through Nanostructured Lipid Carriers in an Experimentally Induced Arthritis Model. Colloids Surf. B Biointerfaces. 2016;147:17–24. doi: 10.1016/j.colsurfb.2016.07.046.

10. Szumała P., Macierzanka A. Topical Delivery of Pharmaceutical and Cosmetic Macromolecules Using Microemulsion Systems. Int. J. Pharm. 2022;615:121488. doi: 10.1016/j.ijpharm.2022.121488.

11. Gupta R., Dwadasi B.S., Rai B., Mitragotri S. Effect of Chemical Permeation Enhancers on Skin Permeability: In Silico Screening Using Molecular Dynamics Simulations. Sci. Rep. 2019;9:1456. doi: 10.1038/s41598-018-37900-0. [PMC free article]

12. Saka R., Jain H., Kommineni N., Chella N., Khan W. Enhanced Penetration and Improved Therapeutic Efficacy of Bexarotene via Topical Liposomal Gel in Imiquimod Induced Psoriatic Plaque Model in BALB/c Mice. J. Drug Deliv. Sci. Technol. 2020;58:101691. doi: 10.1016/j.jddst.2020.101691.

13. Pandi P., Jain A., Kommineni N., Ionov M., Bryszewska M., Khan W. Dendrimer as a New Potential Carrier for Topical Delivery of SiRNA: A Comparative Study of Dendriplex vs. Lipoplex for Delivery of TNF-$α$ SiRNA. Int. J. Pharm. 2018;550:240–250. doi: 10.1016/j.ijpharm.2018.08.024.

14. Sarathlal K.C.S., Kakoty V., Krishna K.V., Dubey S.K., Chitkara D., Taliyan R. Neuroprotective Efficacy of Co-Encapsulated Rosiglitazone and Vorinostat Nanoparticle on Streptozotocin Induced Mice Model of Alzheimer Disease. ACS Chem. Neurosci. 2021;12:1528–1541. doi: 10.1021/ACSCHEMNEURO.1C00022/ASSET/IMAGES/MEDIUM/CN1C00022_M001.GIF.

15. Nafisi S., Maibach H.I. Cosmetic Science and Technology: Theoretical

Principles and Applications. Elsevier; Amsterdam, The Netherlands: 2017. Nanotechnology in Cosmetics; pp. 337–369.

16. Tiwari N., Osorio-Blanco E.R., Sonzogni A., Esporr\'\in-Ubieto D., Wang H., Calderon M. Nanocarriers for Skin Applications: Where Do We Stand? Angew. Chem. Int. Ed. 2022;61:e202107960. doi: 10.1002/anie.202107960. [PMC free article]

17. Shukla T., Upmanyu N., Agrawal M., Saraf S., Saraf S., Alexander A. Biomedical Applications of Microemulsion through Dermal and Transdermal Route. Biomed. Pharmacother. 2018;108:1477–1494. doi: 10.1016/j.biopha.2018.10.021.

18. Nastiti C.M.R.R., Ponto T., Abd E., Grice J.E., Benson H.A.E., Roberts M.S. Topical Nano and Microemulsions for Skin Delivery. Pharmaceutics. 2017;9:37. doi: 10.3390/pharmaceutics9040037.

19. Aithal G.C., Narayan R., Nayak U.Y. Nanoemulgel: A Promising Phase in Drug Delivery. Curr. Pharm. Des. 2020;26:279–291. doi:10.2174/1381612826666191226100241.

20. Anand K., Ray S., Rahman M., Shaharyar A., Bhowmik R., Bera R., Karmakar S. Nano-Emulgel: Emerging as a Smarter Topical Lipidic Emulsion-Based Nanocarrier for Skin Healthcare Applications. Recent Pat. Antiinfect. Drug Discov. 2019;14:16–35. doi: 10.2174/1574891X14666190717111531.

21. Murthy S.N. Approaches for Delivery of Drugs Topically. AAPS PharmSciTech. 2019;21:1–2. doi: 10.1208/s12249-019-1582-x.

22. Iqbal M.A., Md S., Sahni J.K., Baboota S., Dang S., Ali J. Nanostructured Lipid Carriers System: Recent Advances in Drug Delivery. J. Drug Target. 2012;20:813–830. doi: 10.3109/1061186X.2012.716845.

23. Bhowmik D., Gopinath H., Kumar B.P., Duraivel S., Kumar K.P.S. Recent Advances In Novel Topical Drug Delivery System. Pharma Innov. J. 2012;1:12–31.

24. Gannu R., Palem C.R., Yamsani V.V., Yamsani S.K., Yamsani M.R. Enhanced Bioavailability of Lacidipine via Microemulsion Based Transdermal Gels: Formulation Optimization, Ex Vivo and in Vivo Characterization. Int. J. Pharm. 2010;388:231–241. doi: 10.1016/j.ijpharm.2009.12.050.

25. Bhaskar K., Anbu J., Ravichandiran V., Venkateswarlu V., Rao Y.M. Lipid Nanoparticles for Transdermal Delivery of Flurbiprofen: Formulation, in Vitro,

Ex Vivo and in Vivo Studies. Lipids Health Dis. 2009;8:1–15. doi: 10.1186/1476-511X-8-6. [PMC free article]

26. Zhou J., Zhou M., Yang F.F., Liu C.Y., Pan R.L., Chang Q., Liu X.M., Liao Y.H. Involvement of the Inhibition of Intestinal Glucuronidation in Enhancing the Oral Bioavailability of Resveratrol by Labrasol Containing Nanoemulsions. Mol. Pharm. 2015;12:1084–1095. doi: 10.1021/mp5005838.

27. Chang R.K., Raw A., Lionberger R., Yu L. Generic Development of Topical Dermatologic Products: Formulation Development, Process Development, and Testing of Topical Dermatologic Products. AAPS J. 2013;15:41–52. doi: 10.1208/s12248-012-9411-0.

28. Cevc G. Lipid Vesicles and Other Colloids as Drug Carriers on the Skin. Adv. Drug Deliv. Rev. 2004;56:675–711. doi: 10.1016/j.addr.2003.10.028.

29. Chellapa P., Mohamed A.T., Keleb E.I., Elmahgoubi A., Eid A.M., Issa Y.S., Elmarzugi N.A. Nanoemulsion and Nanoemulgel as a Topical Formulation. IOSR J. Pharm. 2015;5:43–47.

30. Marto J., Baltazar D., Duarte A., Fernandes A., Gouveia L., Militão M., Salgado A., Simões S., Oliveira E., Ribeiro H.M. Topical Gels of Etofenamate: In Vitro and in Vivo Evaluation. Pharm. Dev. Technol. 2015;20:710–715. doi: 10.3109/10837450.2014.915571.